Decheng Capital LLC Equillium, Inc. Call Options Transaction History
Decheng Capital LLC
- $422 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding EQ
# of Institutions
27Shares Held
11.3MCall Options Held
0Put Options Held
0-
Decheng Capital Management Iii (Cayman), LLC4.45MShares$3.02 Million1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA842KShares$572,5240.0% of portfolio
-
Cota Capital Management, LLC San Francisco, CA562KShares$382,3491.86% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny321KShares$218,3970.0% of portfolio
-
Geode Capital Management, LLC Boston, MA204KShares$138,9810.0% of portfolio
About Equillium, Inc.
- Ticker EQ
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,352,100
- Market Cap $23.4M
- Description
- Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...